江西金水宝制药

Jiangxi Jinshuibao Pharmaceutical is a prominent Chinese pharmaceutical company specializing in the research, development, and production of Traditional Chinese Medicine (TCM) products. The company is best known for its flagship product, Jinshuibao, which is derived from the fermented mycelium of the Cordyceps sinensis fungus (Cs-4 strain). This product is widely used in China for treating chronic respiratory diseases, renal dysfunction, and enhancing immune function. In 2013, the company was acquired by Jichuan Pharmaceutical Group, a major player in the Chinese healthcare market. Jinshuibao Pharmaceutical operates large-scale manufacturing facilities that adhere to Good Manufacturing Practice (GMP) standards and continues to be a leader in the modernization of fungal-based medicines.